Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
A 26.68 1.60% 0.42
ZGNX closed up 1.6 percent on Friday, March 4, 2022, on 3.15 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 2.62%
Pocket Pivot Bullish Swing Setup 2.62%
Volume Surge Other 2.62%
Calm After Storm Range Contraction 2.62%
Narrow Range Bar Range Contraction 2.62%
NR7 Range Contraction 2.62%
Parabolic Rise Strength 2.62%
Wide Bands Range Expansion 2.62%
Above Upper BB Strength 2.62%
Shooting Star Candlestick Bearish 2.93%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zogenix, Inc. Description

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Pain Opioids Schizophrenia Chronic Pain Central Nervous System Disorders Nervous System Disorders Neurochemistry Migraine Morphinans Ketones Bipolar Disorder Headache Cell Signaling Retail Pharmacies Treatment Of Central Nervous System Disorders Treatment Of Migraine Hydrocodone Severe Chronic Pain Indoles Moderate To Severe Chronic Pain Pharmaceutical Distributors Relday Triptans

Is ZGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.9
52 Week Low 11.03
Average Volume 3,180,751
200-Day Moving Average 17.33
50-Day Moving Average 22.56
20-Day Moving Average 26.24
10-Day Moving Average 26.26
Average True Range 0.35
RSI 77.73
ADX 68.05
+DI 46.84
-DI 6.41
Chandelier Exit (Long, 3 ATRs) 25.85
Chandelier Exit (Short, 3 ATRs) 27.05
Upper Bollinger Bands 26.51
Lower Bollinger Band 25.97
Percent B (%b) 1.32
BandWidth 2.06
MACD Line 0.93
MACD Signal Line 1.21
MACD Histogram -0.2786
Fundamentals Value
Market Cap 1.49 Billion
Num Shares 55.7 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -8.04
Price-to-Sales 158.59
Price-to-Book 2.91
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.27
Resistance 3 (R3) 27.27 27.09 27.17
Resistance 2 (R2) 27.09 26.94 27.08 27.13
Resistance 1 (R1) 26.88 26.85 26.99 26.88 27.10
Pivot Point 26.70 26.70 26.75 26.69 26.70
Support 1 (S1) 26.49 26.55 26.60 26.49 26.26
Support 2 (S2) 26.31 26.46 26.30 26.23
Support 3 (S3) 26.10 26.31 26.19
Support 4 (S4) 26.10